MOLECULAR INCLUSION COMPLEXATION IN GAMA-CYCLODEXTRIN AS AN ALTERNATIVE PHARMACEUTICAL FORM TO DELIVER DOCETAXEL

DTX clinical application is limited by its low water solubility (5 mg/L or 6 uM), low selective distribution and rapid elimination. Also, adverse effects are associated with the use of commercially available DTX formulations such as neutropenia, hypersensitivity reactions, peripheral neuropathy, musculoskeletal toxicity and nasolacrimal duct stenosis. One strategy to overcome such adverse effects and increase DTX anticancer potential would be the complexation with cyclodextrins (CD). In here we report results on the characterization of a DTX-gama-cyclodextrin(g-CD) complex, developed to improve the pharmacological properties of this anticancer agent. As expected, complexation significantly (26-fold) increased the aqueous solubility of DTX. The in vitro release kinetics and cytotoxicity against MCF-7 cancer cells are being evaluated.